Press Release: FDA approves Novartis Kisqali(R) -3-

22. American Cancer Society. Cancer Facts and Figures. Published 2024.

Available

at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-a

nd-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-

figures-acs.pdf. Accessed September 2024.

23. Gomis R, Gawrzak S. Tumor cell dormancy. Mol Oncol. 2017;11(1):62-78.

24. Curigliano G, Ciruelos E, et al. Meta analysis of ET control arms in

adjuvant trials. Presented at the American Society of Clinical Oncology

Annual Meeting; May 31, 2024; Chicago, USA.

25. Clinicaltrials.gov. NCT03701334. A Trial to Evaluate Efficacy and Safety

of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients

With HR+/ HER2- Early Breast Cancer (NATALEE). Accessed September 2024.

https://clinicaltrials.gov/study/NCT03701334

26. Kisqali. Summary of product characteristics (SmPC). Novartis Europharm

Limited; 2017. Accessed September 2024.

https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf.

27. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)) -

Breast Cancer. NCCN Guidelines. Published March 2023. Available at:

https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed

September 2024.

28. European Society for Medical Oncology -- Magnitude of Clinical Benefit

Scale Scorecard. Published April 20, 2020. Updated August 21, 2020.

Available

at: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorec

ard-158-1/. Accessed September 2024.

29. European Society for Medical Oncology -- Magnitude of Clinical Benefit

Scale Scorecard. Published March 29, 2022. Available at:

https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-9-1/.

Accessed September 2024.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Anja von Treskow +41 79 392 9697

Anna Schäfers +41 79 801 7267 Michael Meo +1 862 274 5414

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line:

+41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Isabella Zinck +41 61 324 7188 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Jonathan Graham +1 201 602 9921

Imke Kappes +41 61 324 8269 Parag Mahanti +1 973 876 4912

(END) Dow Jones Newswires

September 17, 2024 12:55 ET (16:55 GMT)